Immix Biopharma Inc
$2.37
(as of Jun 6, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Immix Biopharma Inc
Stock Price
$2.37
Ticker Symbol
IMMX
Exchange
NASDAQ
Industry Information for Immix Biopharma Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Fundamentals for Immix Biopharma Inc
Market Capitalization
$72,480,976
EBITDA
$-21,699,388
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.69
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
27,877,300
Percent Owned by Insiders
40.85%
Percent Owned by Institutions
12.27%
52-Week High
52-Week Low
Technical Indicators for Immix Biopharma Inc
Analyst Ratings for Immix Biopharma Inc
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
News About Immix Biopharma Inc
Jun 6, 2025, 9:39 AM EST
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. See more.
Jun 3, 2025, 2:55 PM EST
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
See more.
May 23, 2025, 9:05 AM EST
– Patient enrollment exceeding expectations –
See more.
May 22, 2025, 4:02 PM EST
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety.
See more.